Health · Pharma & Biotech · 3 days ago
Curium sets Bexlutry price about 5% below Lutathera
Curium has set a list price for Bexlutry at $63,524 per infusion.
Bexlutry is a radioligand medicine described as a radiosimilar to Lutathera.
Lutathera is made by Novartis.
Bexlutry’s price is about 5% lower than Lutathera’s cost.
The price difference matters because it makes Bexlutry the lower-priced option of the two.
No further steps or changes are specified.
Curium set Bexlutry’s list price at $63,524 per infusion.
The price is about 5% below that of Novartis’ Lutathera.
Bexlutry is described as a radiosimilar to Lutathera.
The article does not state when Bexlutry will become available.
- Who
- Curium set the price for Bexlutry.
- What
- Bexlutry was priced at $63,524 per infusion, about 5% below Lutathera.
- When
- Not stated
- Where
- Not stated
- Why
- Not stated
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Bexlutry list price
- $63,524 per infusion
- Price difference
- About 5% below Lutathera
- Company
- Curium
- Comparator drug
- Novartis’ Lutathera
Sources
Related news
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
